Abstract Hydroxyurea (HU) is frequently given as treatment for myelofibrosis (MF), but data on its efficacy and tolerability are scarce. The results of HU therapy were evaluated in 40 patients with hyperproliferative manifestations of primary (n=32), post-polycythemia vera (n=6), or post-essential thrombocythemia (n=2) myelofibrosis. Median interval between diagnosis and HU start was 6.2 months (range 0-141.7). Reasons for treatment were constitutional symptoms (55%), symptomatic splenomegaly (45%), thrombocytosis (40%), leukocytosis (28%), pruritus (10%), and bone pain (8%). The starting dose was 500 mg/ day, subsequently adjusted to the individual efficacy and tolerability. Response was bone pain 100%, constitutional symptoms 82%, pruritus 50%, splenomegaly 40%, and anemia 12.5%. According to the International Working Group for Myelofibrosis Research and Treatment criteria, clinical improvement was achieved in 16 patients (40%). Median duration of response was 13.2 months (range 3-126.2). Worsening of the anemia or appearance of pancytopenia were observed in 18 patients, requiring administration of erythropoietin-stimulating agents (n=17) and/or danazol (n=9). Oral or leg ulcers appeared in five patients and one had gastrointestinal symptoms. HU is an effective and generally well-tolerated therapy for the hyperproliferative manifestations of MF. The accentuation of the anemia often induced by HU is usually manageable with concomitant treatment.
Introduction
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) of clonal origin [1] characterized by bone marrow fibrosis, extramedullary hemopoiesis with splenomegaly, anemia with dacryocytes, and a leukoerythroblastic blood picture [2] . MF can present as a de novo disorder (primary myelofibrosis or PMF) or appear as an evolutive form of a previously known polycythemia vera or essential thrombocythemia (post-PV MF or post-ET MF) [3] . The recent finding of the V617F mutation in the JAK2 gene in a high proportion of MF patients [4] and the MPL mutation in some PMF patients [5] has contributed to a better understanding of the pathogenesis of the disease.
From the clinical point of view, MF is a heterogeneous disorder, with its spectrum ranging from patients who are asymptomatic at diagnosis and may not require treatment for years to others with symptoms mainly derived from anemia and splenomegaly and constitutional symptoms [6] . Except for allogeneic hemopoietic stem cell transplantation (allo-HSCT) [7, 8] , therapy of MF remains mostly palliative and is usually adjusted to the disease characteristics in each patient [6] . In the "hyperproliferative" forms of the disease, characterized by constitutional symptoms, marked splenomegaly, leukocytosis, and/or thrombocytosis, and, more rarely, aquagenic pruritus or bone pain, cytolytic treatment is usually administered [6] . Although hydroxyurea (HU) is the drug most frequently used in such cases, information on its efficacy is limited to a few reports including a scarce number of patients [9, 10] . In this context, the introduction in clinical trials of the JAK2 inhibitors, which seem to be effective for the hyperproliferative manifestations of MF [11] [12] [13] , has raised the need for information on the results of conventional therapy in such patients.
The aim of the present study was to analyze, using modern criteria of response, the efficacy, and tolerability of HU in 40 patients with hyperproliferative manifestations of MF treated in a single institution.
Patients and methods
Among 157 subjects consecutively diagnosed with PMF (n=127), post-ET (n=20), or post-PV (n=10) MF at the Hematology Department of the Hospital Clínic of Barcelona between 1991 and 2008, 40 patients received HU as treatment for hyperproliferative manifestations of MF, including constitutional symptoms (weight loss, night sweats, low grade temperature), symptomatic splenomegaly, pruritus, bone pain, leukocytosis, and thrombocytosis. The latter 40 patients are the subject of the present study and their main characteristics are described in the "Results" section. The diagnosis of MF was made according to the criteria accepted at the time when the patients were diagnosed, but in all cases, the current WHO criteria [14] were fulfilled.
In addition to the patients' demographic data, the following variables were analyzed: type of symptoms or reason for starting HU, time lapse between MF diagnosis and initiation of HU, response to treatment, time to response, maintenance HU dose, length of response, need for additional therapies during HU treatment (i.e., use of erythropoietin, darbepoetin-alfa or androgens), and HUrelated side effects. The latter included worsening of the anemia, defined as a decrease in the Hb level below 10 g/L or need for transfusion, development of cytopenias, appearance of oral or leg ulcers, and gastrointestinal symptoms. A complete medical history, physical examination, blood counts, and comprehensive biochemistry tests were obtained before the start of HU and at appropriate intervals, which varied depending on the patients' clinical situation but did not exceed 3 months in any case. The starting HU dose was 500 mg daily, and it was subsequently modified according to the efficacy and tolerability in each patient. The clinical end-point for titrating the HU dosage was the disappearance of the symptoms that motivated HU start or the improvement or normalization of the clinical and hematological parameters (spleen size in case of symptomatic splenomegaly, and leukocyte and platelet counts in case of leukocytosis or thrombocytosis) that led to HU institution. In a proportion of patients, the subsequent appearance of hematologic and non-hematologic toxicity led to a dose reduction.
The response was evaluated using the criteria of the European Myelofibrosis Network (EUMNET) [15] and those of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) [16] . The minimum time to assess the response was established as 3 months. In case of appearance or worsening of a preexisting anemia, either erythropoietin/darbepoetin-alfa or danazol were administered, depending on the patient's serum erythropoietin levels, as previously reported [17] [18] [19] .
Results Table 1 shows the main characteristics of the 40 patients. As can be seen, most patients had PMF. Median interval between MF diagnosis and HU start was 6.2 months (range 0-141.7). The indications for starting HU treatment were constitutional symptoms (n = 22, 55%), symptomatic splenomegaly (n=18, 45%), thrombocytosis (n=16, 40%), leukocytosis (n=11, 28%), pruritus (n=4, 10%), and bone pain (n=2, 8%). As can be inferred from the above figures, some patients had more than one feature of hyperproliferation, including 20 patients with two and four with three or more features. Table 2 shows the therapeutic response for each hyperproliferative feature using the EUMNET criteria. According to these criteria, overall clinical and hematological response . In responding patients, median maintenance daily HU dose was 700 mg (range 500-2,000). Hematologic toxicity was observed in 18 patients (45%), consisting of the appearance or worsening of a preexistent anemia (n=14) or pancytopenia (n=4). Overall, 26 patients required concomitant administration of erythropoietin/darbepoetin-alfa (n=17) or danazol (n=9) due to anemia at HU start or that appeared or worsened during HU therapy. Twelve patients responded to erythropoietin or darbepoetin-alfa. On turn, seven patients responded to danazol, but in all cases, the responses were short-lived. Median HU dose received by patients who develop HU-induced anemia was 643 mg/day (range 143-1,500) versus 1,000 mg/day (range 143-1,500) for patients not requiring a specific treatment for the anemia, with the difference between the two groups not being significant (Mann-Whitney U test). Non-hematologic side effects consisted of oral or leg ulcers, which were observed in five patients (12.5%), and gastrointestinal symptoms in one patient (2.5%). Median daily HU dose in patients developing ulcers was 1,340 mg (range 500-2,000).
At this writing, 26 patients have died. Causes of death included disease progression (n=8, including acute transformation, observed in five patients), infection (n=5), bleeding (n=3), thrombosis (n=3), complications of allo-HSCT (n=2), liver failure and cardiac insufficiency (one case each), and unknown causes (three patients). Of the 14 patients alive, 13 continue receiving HU. Among nonresponders, five patients eventually developed acute transformation, at a median of 18.8 months (range 11.9-25.3) from HU start, two received a standard or a reduced intensity conditioning allo-HSCT and died from complications related to the procedure, and two required splenectomy or splenic radiation as salvage therapy for symptomatic splenomegaly.
Discussion
Except for allo-HSCT [7, 8] , the therapy of MF remains essentially palliative and is usually adjusted to the characteristics of the disease in every individual [6] . Thus, a waitand-see approach is often adopted in asymptomatic patients, delaying treatment start until a change in the clinical situation is observed. In patients with anemia, besides transfusion therapy, treatment is based on the use of androgens [19, 20] , erythropoietin or erythropoietinstimulating agents [17, 18] , and, more recently, immuuomodulatory drugs such as thalidomide, lenalidomide, or pomalidomide [21] [22] [23] . With regard to symptoms of hyperproliferation of MF, they are usually managed with oral cytoreductive drugs, not only HU [9, 10] but also busulfan [24] or melphalan [25] . Other treatment modalities include interferon-alfa [26] , as well as splenectomy [27] or splenic radiation [28] for symptomatic splenomegaly refractory to drug treatment. However, a substantial proportion of patients does not respond to the above therapies or fail after achieving a response. This fact has stimulated the search for newer, more effective therapies for MF. In this sense, the discovery of the JAK2 mutation [4] has been taken as a basis for the development of molecularly targeted therapies, the so-called JAK2 inhibitors. The preliminary results of the clinical trials with these drugs indicate their efficacy in the hyperproliferative manifestations of MF [11] [12] [13] . Therefore, for comparison purposes, HU seems to be the logical reference.
Although HU is widely used in MF, published data on its efficacy and tolerability in these patients are limited. Löfvenberg et al [9] reported the therapeutic results in 10 PMF patients, who were part of a series of 59 MPN patients treated with HU, reporting a favorable response in 8 of them. Although toxicity was considered moderate, 21 episodes of accentuation of anemia were registered during HU treatment. In some patients, the response was associated with reversal of bone marrow fibrosis [29] . On turn, Manoharan [10] described the results of intermittent HU therapy in 10 PMF patients. In this latter study, in which HU was administered twice or thrice weekly at a dose of 1 to 2 g to treat hyperproliferative manifestations of MF, Responses include complete plus partial response according to the EUMNET criteria four patients had a good response and four a partial response, with no hematologic toxicity being observed. It must be remarked that both studies, in addition to including a small number of patients, had the limitation of the lack of well-recognized criteria of response in MF at that time.
The present study included 40 MF patients who were uniformly treated at the same institution and in whom the response to treatment was assessed using modern criteria of response [15, 16] . In a substantial proportion of patients, HU was effective in controlling the manifestations of MF, especially the hyperproliferative signs or symptoms, and, overall, 40% of the patients fulfilled the stringent IWG-MRT category of clinical improvement [16] . Median duration of the response exceeded one year, although there was a wide variability. The HU dose necessary to maintain the response was also variable, ranging from 500 mg to 2 g daily. Of note, five of the 24 resistant patients eventually developed acute transformation.
In our patients, HU therapy was often associated with hematologic and non-hematologic side effects. Accentuation of anemia was the most frequent adverse effect, being observed in almost a half of the patients. This complication could be successfully managed in many cases with the addition of erythropoietin or erythropoietin-stimulating agents, especially in patients with inadequate erythropoietin serum levels and non-transfusion-dependent anemia. In patients not eligible for the above agents because of their adequate erythropoietin levels or who did not respond to them, responses could also be obtained with danazol, but they were usually short-lived. Although the difference was not significant, as a whole, patients with HU-induced anemia received less HU than patients not requiring the addition of a specific treatment for the anemia. This fact should not be surprising, since development or worsening of a pre-existing anemia was considered as a side effect of HU and, as such, it led to lower dose escalation or to dose reduction. With regard to non-hematologic toxicity, oral or leg ulcers were the most frequently registered side effect, although they were observed in a minority of patients.
In conclusion, HU is an effective and relatively welltolerated therapy for the hyperproliferative manifestations of MF. Accentuation of the anemia, usually manageable with concomitant therapy, is the most frequent side effect of treatment. Durability of the responses is variable, but can be long-lasting. Anyway, given the palliative nature of HU, newer more effective and durable therapies for the hyperproliferative forms of MF are needed.
